Trials / Unknown
UnknownNCT05189184
Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The First Affiliated Hospital of Zhengzhou University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-labelled study to evaluate the efficacy and safety of Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Metastatic or Recurrent, UnresectableHead and Neck Squamous Cell Carcinoma. The objective response rate (ORR) will be evaluated as the primary endpoints.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin | Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Recurrent or Metastatic , UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC) |
Timeline
- Start date
- 2022-03-30
- Primary completion
- 2025-03-30
- Completion
- 2025-03-30
- First posted
- 2022-01-12
- Last updated
- 2022-01-12
Source: ClinicalTrials.gov record NCT05189184. Inclusion in this directory is not an endorsement.